Figure 6
Treatment of anti-ckit antibody significantly improves the long-term survival rate of mice treated with immune modulatory therapy of IL-12 plus 4-1BB activation. Mice bearing large MCA26 tumors (10 × 10 mm2) in the liver were divided into the following treatment groups: DL312 (control viral vector) plus control Ig; DL312 plus anti-ckit; Adv.mIL-12 plus anti–4-1BB plus rat Ig; Adv.mIL-12 plus anti–4-1BB plus anti-ckit; Adv.mIL-12 plus anti-ckit; and DL312 plus anti–4-1BB plus anti-ckit. The survival advantage for the mice treated with Adv.mIL-12 plus anti–4-1BB plus anti-ckit was statistically significant compared with those treated with Adv.mIL-12 plus anti–4-1BB plus rat Ig (P < .01, log-rank test).
